Last checked at 26 Jul 2018 07:00
Shield Therapeutics plc
("Shield" or the "Company")
Appointment of Non-Executive Director
London, UK, 26 July 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing iron deficiency, is pleased to announce the appointment of Hans-Peter Hasler as a Non-Executive Director of the Company with immediate effect.
Mr Hasler is the founder and CEO of Vicarius Pharma and an Advisor to SBTech Global Advisory. His prior experience includes roles as COO, Elan Corporation, and several senior positions at Biogen, Inc., including Chief Operations Officer. Previously, Mr. Hasler was at Wyeth Pharmaceuticals as Senior Vice President, Chief Marketing Officer and Managing Director of Wyeth Group Germany, Wyeth-Lederle Switzerland, Austria and CEE. Mr Hasler is Chairman of HBM Healthcare Investments AG in Switzerland, Chairman of MIAC Medical Imaging Analysis Center of the University Hospital of Basel, and a Director of the Board of Minerva Neuroscience Inc., Boston.
Carl Sterritt, CEO of Shield Therapeutics, said: "On behalf of the Board I'd like to welcome Hans-Peter to Shield and trust his broad experience of commercial operations and negotiations in pharmaceutical transactions will be a great asset to the Company in the coming months and beyond."
Regulatory Disclosures
The following disclosures are required regarding Hans-Peter's appointment pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:
Full name and age: Hans-Peter Hasler, aged 62
Hans-Peter holds or has held the following directorships in the five years preceding his appointment at the Company:
Current Directorships | Former Directorships |
HBM Healthcare Investment AG | Acino Holding AG |
MIAC AG | AOP Orphan Pharmaceuticals |
Minerva Neuroscience Inc. | Celltrion Inc. |
Vicarius Pharma AG | Dr Reddy's Labs |
| Ferring Holding S.A. |
| Pantheon N.V. |
| Rigi Healthcare AG |
No further disclosure is required under AIM Rule 17 and paragraph (g) to Schedule Two of the AIM Rules with respect to Hans-Peter Hasler.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)207 186 8500
Carl Sterritt, Chief Executive Officer
Nominated Advisor and Joint Broker +44 (0)203 100 2222
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker +44 (0)207 418 8900
Peel Hunt LLP
James Steel/ Dr Christopher Golden
Financial PR Advisor +44 (0)203 709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs. Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives. The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com.